As part of our Ethical Scientific Research policy, we commit to developing **Layperson Summaries of Clinical Trial Results** for Phase 2-4 trials of our medicines and vaccines.

We develop summaries within 6 months of study completion for trials in paediatric population and within 12 months for trials in adults.

We translate the summaries into all languages of the informed consent form. This includes rare languages such as Kiswahili, Cyrillic, Dhulu.

We distribute our summaries to the investigators of our trials to share with trial participants.

We post our Layperson Summaries publicly on:

- **GSK Study Register**: gsk-studyregister.com
- **Trial Summaries**: www.trialsummaries.com

GSK would like to thank all participants and their families for their contribution to the development of our medicines and vaccines.
We follow good writing practices so that our summaries fulfil five key requirements:

**Plain Language**
Use of simple language to ensure clarity and understanding while keeping the content direct not promoting any product.

**Health Literacy Principles**
Ensure the text is suitable for all by avoiding technical jargon, unfamiliar words, and complex medical terms.

**Numbers and Data**
Tailor content to meet the needs of all by presenting whole numbers rather than decimals, using percentages for better understanding when presenting numerical data.

**Visual Appeal**
Use creative solutions for illustrations of statistical data, results, study designs while striking a balance between visual format and text.

**Readability Score**
Verify readability score of each summary using well-accepted reading scores such as Flesch-Kincaid Readability score.

The content of our Layperson Summaries of Clinical Trial Results are aligned to the requirements of the European Clinical Trial Regulation 536/2014 and include:

- Study names
- Who sponsored the trial
- General information about the clinical trial
- Which participants were included in this trial
- Which medicines were studied
- The main results of the trial
- What the side effects were
- How the trial has helped participants and researchers
- Plans for further studies
- Where to find more information about the trial